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WE examined the effect of the immunosuppressive
agent, tacrolimus (FK506), on antigen-induced bron-
chial hyperreactivity to acetylcholine and leukocyte
infiltration into the airways of ovalbumin-challenged
guinea-pigs. Subcutaneous injection of 0.5mg/kg  of
FK506,  1h  before  and  5h  after  intra-nasal antigen
challenge  prevented  bronchial  hyperreactivity  to
aerosolized acetylcholine, eosinophilia in bronchoal-
veolar  lavage  (BAL)  fluid  and  bronchial  tissue  and
the  invasion  of  the  bronchial  wall  by  CD4+
T-lymphocytes.  FK506  also  suppressed  ovalbumin-
induced increase in the number of leukocytes adher-
ing  to  the  pulmonary  vascular  endothelium  and
expressing a 4-integrins. Inhibition by FK506 of anti-
gen-induced bronchial hyperreactivity  in sensitized
guinea-pigs may thus relate to its ability to prevent
the  emergence  of  important  inflammatory  compo-
nents  of  airway  inflammation,  such  as  eosinophil
accumulation, as well as CD4+ T-lymphocyte infiltra-
tion into the bronchial tissue.
Key  words:  T-lymphocytes,  Eosinophils,  Immunohisto-
chemistry, Immunosuppressive drugs, a 4-integrins
Introduction
Despite  the  increasing  knowledge  regarding  the
pathogenesis  of  asthma,  its  prevalence,  number  of
hospital admissions due to acute exacerbations, and
its mortality increase continuously in most parts of
the  world.1 The  complex  cascade of  inflammatory
events that leads to chronic asthma, with the develop-
ment of mucosal inflammation and bronchial hyper-
reactivity, becomes increasingly apparent. The impor-
tance  of  the  association  between  T-lymphocytes,
particularly of the CD4+ subset, and eosinophils in the
pathogenesis  of  the  disease  is  now  well  estab-
lished.2–11 However,  some  mechanisms  involved  in
the inflammatory process are still open to doubts.
Using  the  model  of  sensitized  and  challenged
guinea-pigs  to  dissect  the  mechanisms  of  allergic
airway  inflammation,12 we  have  shown  that  the
development of bronchial hyperreactivity is chrono-
logically  associated  with  infiltration  of  CD4+
T-lymphocytes  and  eosinophils  in  the  bronchial
wall.13,14 We also demonstrated that the mere pres-
ence of eosinophils in the bronchial mucosa is not
necessarily translated into bronchial hyperreactivity.
Activation of these cells by certain mediators, such as
leukotriene B4,  with  the subsequent  release of the
cationic  proteins,  including  major  basic  protein
(MBP) and eosinophil peroxidase (EPO), is required
for  the  development  of  marked  bronchial  hyper-
reactivity to methacholine.15
Mobilization  of  leukocytes  into  inflamed  tissues
requires the induction, on their surface, of adhesion
molecules that are capable of interaction with their
ligands  expressed  on  endothelial  cells.  It  has  been
shown that the expression of ICAM-1 on inflamma-
tory cells is essential for the acquisition of bronchial
hyperreacticity  in  primates.16 The  family  of  the
a 4-integrins also plays a considerable role in allergic
inflammation.17 We  have  indeed demonstrated that
treatment  of  aerosol-sensitized  guinea-pigs  with  an
antibody directed against a 4- integrins prevents the
development  of  bronchial  hyperreactivity  and  the
associated increase in the number of CD4+ T-cells and
eosinophils infiltrating the bronchial mucosa.18
Modulation of the bronchial inflammation by glu-
cocorticosteroids  is  now  the  cornerstone  for  the
treatment  of  asthma.1 Other  classes  of  anti-inflam-
matory  and  immunosuppressive  drugs,  such  as
cyclosporin-A  and  tacrolimus  (FK506),  a  macrolide
with  intense  immunosuppressive  activity  resulting
mostly  from  the  inhibition  of  T-cell  activation,19
have  also  been  investigated  in  experimental  sys-
tems. The further observations showing that FK506
prevents  cytokine  and  mediator  release  from  mast
cells20,21 suggested  its  potential  usefulness  in  aller-
gic  inflammation.
In the present study, we used FK506 as a tool to
evaluate inflammatory changes in the lungs following
multiple intra-nasal (i.n.) antigen challenges in aero-
sol-sensitized animals.
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Guinea-pig sensitization
Male Hartley guinea-pigs (400–600g, Charles River, St
Aubin-les-Elbeuf, France) were immunized by aeroso-
lized ovalbumin (Miles Naperville, IL, USA), at 1% in
sterile 0.9% NaCl (saline) during 30min. The proce-
dure was repeated 48h later and the animals were
exposed to antigen challenge 14 to 17 days after the
first inhalation.18The aerosol was delivered into a 36L
plexiglass chamber using a DeVilbiss ultrasonic nebu-
lizer  (Ultra-Neb  99,  DeVilbiss  Medical,  Arcueil,
France), which produced particles of a mass diameter
averaging between 0.5 and 3m m. The liquid output of
the  nebulizer  was  0.6ml/min.  The  day  of  antigen
provocation, guinea-pigs received an intraperitoneal
(i.p.)  injection  of  4mg/kg  mepyramine  maleate
(Sigma,  St  Louis,  MO)  and,  15min  later,  increasing
concentrations of  ovalbumin  (0.001%,  0.01%,  0.1%,
0.5% and 1%) were administered into the nostrils of
each sensitized animal in a volume of 200m l, every
15min.
Control guinea-pigs were sensitized as above and
received i.n. sterile saline, in place of ovalbumin. The
animals were used 6, 24 or 72h after challenge for
cellular and MBP determinations in the BAL fluid and
bronchial tissue and 72h after challenge for measure-
ment of bronchial hyperreactivity. Each experimental
group was composed of six animals, unless otherwise
stated.
Treatments
FK506  was  administered  subcutaneously  (s.c.)  to
sensitized guinea-pigs, at the dose of 0.5mg/kg, 1h
before and 5h after antigen challenge. The drug was
prepared  according  to  instructions  of  the  manu-
facturer: 10mg FK506 were dissolved in 1ml ethanol
(Merck,  Darmstadt,  Germany)  and  0.5ml  of  this
solution  was  mixed  with  0.1ml  Tween  80  (Fluka
Chemika,  Buchs,  Switzerland). The  whole  mixture
was diluted with 4.4ml of sterile saline, to give a final
concentration  of  1mg/ml  FK506.  Dilutions  were
performed in saline. Control animals received similar
amounts  of  vehicle  only,  i.e.  ethanol/Tween  80
injected bys.c. route.
Assessment of bronchial hyperreactivity
The day of the experiment, 72h after the challenge,
guinea-pigs were anaesthetized by an intra-peritoneal
injection  of  30mg/kg  sodium  pentobarbital  (Clin-
Midy Montpellier, France) and tracheae were cannu-
lated. Animals were ventilated with a small respiratory
pump (Biosciences, Sheeness, UK), at 60 strokes/min
and  10 ml/kg  body  weight. The  jugular  vein  was
cannulated  and  spontaneous  breathing  was  sup-
pressed by  the  i.v.  injection of  4mg/kg  of  pancur-
onium bromide (Organon Teknika, Fresnes, France).
Airflow and transpulmonary pressure were measured
and the lung resistance (RL) and dynamic compliance
(Cdyn) were calculated using a computerized pulmo-
nary monitoring system (m Med PMS, London, UK).
At least 1h after surgery, bronchial reactivity was
tested  by  the  aerosol  administration  of  increasing
concentrations  (1,  2,  5,  10,  20  and  50mM)  of
acetylcholine  (Sigma),  at  15-min  intervals  between
each. Six consecutive breaths of each dilution consti-
tuted the challenge dose. Acetycholine was inhaled
using a DeVilbiss ultrasonic nebulizer (Ultra-Neb 99,
DeVilbiss  Medical, Arcueil,  France),  driven by  com-
pressed air and containing 0.5ml of the test solution.
The mass diameter of the particles averaged between
0.5 and 3m m. The liquid output of the nebulizer was
0.6ml/min.
Results  were  expressed  as  the  provocative  dose
(PD)  of  acetylcholine,  calculated  from  the  dose-
response  curve,  required  to  increase  the  RL or  to
decrease the Cdyn by 50cm H2O/(litre/s) (PD50).
Bronchoalveolar cell counts and differentiation
In separate experiments, sensitized guinea-pigs chal-
lenged  either with saline or ovalbumin  and treated
with FK506 or with its vehicle were anaesthetized as
above and tracheae were cannulated. Bronchoalveolar
cells were collected in five successive lavages using
10-ml aliquots of sterile saline at room temperature
injected and  recovered through  a  polyethylene  tra-
cheal cannula. The lavage fluid was stored on ice and
total  cell  counts  were  performed  using  a  Coulter
Counter (model ZM, Coultronics, Margency, France).
An  aliquot  of  the  suspension  was  then  diluted  to
reach a final concentration of 1.5 3 105 cells/ml and
cytospin preparations were performed (Hettich Uni-
versal, Tuttingen, Germany). Differential cell  counts
were  obtained by  counting  300  cells  after  staining
with Diff-Quik® stain (American Scientific Products,
Mc Gaw Park, IL, USA). The results are expressed as
numbers of eosinophils/ml BAL fluid. Aliquots of 1ml
of  the  remaining  lavage  fluid  were  centrifuged  at
200g for  15min  at  4°C  and  the  supernatant  was
collected and stored at-20°C until the determination
of MBP, as described below.
MBP determination by ELISA
Eosinophil MBP (a gift from Dr M.K. Church, South-
ampton  General  Hospital,  Southampton,  UK)  was
purified, reduced, alkylated and dialysed, according to
a modification of the procedure of Gleich et al.22
For the determination of MBP levels in the super-
natants of BAL fluid, the samples were alkylated and
reduced before the assay to avoid polymerization of
the MBP molecule and ELISA was performed using the
mouse anti-guinea-pigmAbs 8A12  and 8D12 (kindly
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plc, Stoke Court, Slough, UK), as previously descri-
bed.15,23,24 The lower detection limit of the assay was
approximately 10ng MBP/ml sample.
Immunohistochemistry
After the BAL collection was performed as described
above,  guinea-pigs  were  exsanguinated  via  the
abdominal  aorta  and  the  contents  of  the  thoracic
cavity resected en bloc. The lungs were inflated via
the  trachea with  3ml  Histocon  (Polysciences, War-
rington, PA, USA), the lobes dissected and mounted
over  cork disks,  covered by  optimum  cutting  tem-
perature  compound  (BDH,  Poole,  UK)  and  snap
frozen in isopentane (Prolabo, Paris, France) cooled
by liquid  nitrogen. The frozen blocks were kept at-
80°C  prior  to  use.  Sections  alongside  the  main
intrapulmonary bronchus were cut in a cryostat kept
at-21°C and collected on glass slides previously coated
with  poly-l-lysine  (Sigma),  fixed  in  chloroform-ace-
tone v/v (Merck) for 10min, wrapped in a plastic film
and kept at-20°C prior to use. Representative sections
of each block were also stained with haematoxylin-
eosin (Rhˆ one-Poulenc, Viliers-Saint Paul, France) for
conventional histology.
Consecutive sections of  each block were stained
with the following monoclonal antibodies, as descri-
bed:14 CT5 = mouse anti-guinea-pig T- lymphocytes,
staining also macrophages and some B cells (provided
by  Dr  R.  Scheper,  Free  University, Amsterdam, The
Netherlands);25 H155  =  rat  anti-guinea-  pig  CD4,
recognizing helper T-lymphocytes (a gift from Drs H
Sch¨ afer and R. Burger, Robert-Koch Institute, Berlin,
Germany);26 CT6 = mouse anti-guinea-pig CD8, recog-
nizing suppressor/cytotoxic T cells (provided by Dr R.
Scheper,  Free  University,  Amsterdam,  The  Nether-
lands);25 HP1/2 = mouse anti-human a 4- integrins27 (a
gift  from  Dr  R.  R.  Lobb, Biogen,  Cambridge, USA),
which cross-reacts with guinea-pig.28 For the murine
antibodies (HP1/2, CT5 and CT6), alkaline phospha-
tase-anti-alkaline phosphatase (APAAP) staining proce-
dure was performed using rabbit immunoglobulin (Ig)
to  mouse  Ig  (Z259,  Dakopatts  a/s,  Copenhagen,
Denmark)  and  mouse  APAAP  (D651,  Dakopatts),
followed by incubation with the substrates Fast Red
TR  (Sigma)  and naphtol AS MX  phosphate (Sigma),
and light  haematoxylin counterstaining. For the rat
antibodies, APAAP staining was also performed, using
rabbit Ig to rat Ig (D455, Dakopats), followed by rat
APAAP (D488,  Dakopatts) and similar development.
Cyanide-resistant EPO activity, employing potassium
cyanide  (Merck),  diaminobenzidine  and  hydrogen
peroxide  (Merck),  was  used  to  stain  the
eosinophils.14,29
At least two sections stained with each antibody or
EPO  technique,  were  coded  and  read  in  a ‘blind’
fashion. Positive cells were enumerated in the bron-
chial  wall  in  two  compartments,  submucosa
(between the basal lamina and the smooth muscle),
and adventitia (between the smooth muscle and the
cartilage),  and  in  the  vessels  (cells  adhered to  the
endothelium  and  infiltrating  the  perivascular  com-
partment), by  means of an eyepiece graticule com-
prising 100 squares of known area. The area of the
compartments and the number of positive cells were
determined on each microscope field, and at least 10
fields were analysed. The results of each stained slide
were expressed as the number of positive cells per
unit  area  (6.25  3 104 m m2,  the  total  area  of  the
graticule).  Results  were  calculated  per  monoclonal
antibody for each experimental group.
Statistical analysis
Results are expressed as mean ± SEM of the indicated
number of experiments. One- way ANOVA was used
to  determine  significance  among  the  groups.  If  a
significant variance was found, an unpaired Student’s
t-test  was  used  to  assess  comparability  between
means.  A  value  of  P =  0.05  was  considered
significant.
Results
Effect of FK506 on antigen-induced bronchial
hyperreactivity in sensitized guinea- pigs
In confirmation to our previous data,24 no changes in
the  intensity  of  bronchial  responsiveness  to  acet-
ylcholine were observed when saline-and ovalbumin-
challenged  animals  were  used  6  or  24h  after  the
challenge (data not shown).
When  compared  with  saline-challenged  animals,
antigen-challenged  vehicle-  injected  guinea-pigs
showed airway hyperreactivity to inhaled acetylcho-
line at 72h, which was expressed by a decrease in
PD50 values for both RL and Cdyn (Fig. 1). Bronchial
hyperreactivity  to  acetylcholine  at  72h  was  sup-
pressed  by  thes.c.  treatment  of  the  animals  with
0.5mg/kg  FK506,  1h  before  and  5h  after  the
challenge (Fig. 1).
Effect of FK506 on antigen-induced eosinophil
accumulation and MBP release in the BAL fluid
of sensitized guinea-pigs
Ovalbumin  inhalation  by  sensitized  vehicle-treated
guinea-pigs  was  followed  by  an  increase  in  the
number of eosinophils in the BAL fluid, which started
at 6h and reached a plateau at 24 and 72h (Fig. 2A).
Treatment  of  the  animals  with  0.5mg/kg  FK506,
injecteds.c.  1h  before  and  5h  after  the  challenge,
decreased markedly eosinophil accumulation in the
BAL  fluid  at  24  and  72h,  without  affecting  sig-
nificantly that observed at 6h (Fig. 2A).
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showed a rise in their BAL concentrations of MBP at
24  and  72h,  but  not  at  6h  (Fig.  2B).  FK506
significantly  inhibited MBP production at 24h (Fig.
2B). A  marked  reduction  in  MBP  release  was  also
noted in  FK506-treated animals  used 72h after the
challenge,  but  the high degree of  variability in  the
control group precluded the results from achieving
statistical significance (90.5% inhibition, n = 6, P >
0.2).
Effect of FK506 on antigen-induced cellular
infiltration in the bronchial mucosa of
sensitized guinea-pigs
Antigen challenge was also followed by  augmented
eosinophil numbers in the bronchial mucosa, which
reached a similar intensity at 6 and 24h, to decline
at  72h  (Fig.  3).  Most  of  the  positive  cells  were
found  in  the  bronchial  submucosa  rather  than  in
the  adventitia  (Fig.  3).  Thes.c.  treatment  of  the
animals with FK506 decreased markedly eosinophil
infiltration  in  the  bronchial  mucosa  at  all  time
points and in both compartments (Fig.  3).
T-lymphocyte recruitment into the bronchial wall
following  antigen  challenge  was  also  curtailed  by
FK506  (Fig.  4).  Indeed,  the  substantial  increase  in
the  numbers  of  CT5+ cells  both  in  the  bronchial
submucosa  and  in  the  adventitia  which  was
observed  at  all  time-points  after  ovalbumin
challenge  was  reduced  significantly  by  FK506
(Fig.  4).
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FIG. 1. Effect of FK506 on antigen-induced bronchial hyper-
reactivity to inhaled acetylcholine in sensitized guinea-pigs.
Bronchial reactivity to inhaled acetylcholine (1–50mM) was
evaluated in saline- and ovalbumin-challenged guinea-pigs,
treateds.c.  with  0.5mg/kg  FK506  or  with  its  vehicle,  1h
before and 5h after the challenge, and used 72h thereafter.
Results are expressed as provocative dose (PD) of acetylcho-
line, calculated from the dose-response curve, required to
increase the RL (panel A) or to decrease the Cdyn (panel B) by
50cm H2O/(litre/s) (PD50). The baseline RL were of 155.7 ±
9.6, 188.3 ± 20.6 and 171.2 ± 10.5cm H2O/(litre/s), and that
Cdyn were of 0.68 ± 0.05, 0.54 ± 0.08 and 0.72 ± 0.06cm H2O/
(litre/s),  for  saline-  and  ovalbumin-challenged vehicle-  or
FK506-treated guinea-pigs, respectively (differences not stat-
istically significant). Data are means ± SEM of 7–9 experi-
ments.  †P <  0.05,  compared  with  ovalbumin-challenged
vehicle-treated guinea-pigs.
FIG. 2. Effect of FK506 on antigen-induced eosinophil accumulation (panel A) and MBP release (panel B) in the BAL fluid from
sensitized guinea-pigs. Sensitized vehicle- or FK506 (0.5mg/kg)-treated animals were challenged with intra-nasal saline or
ovalbumin and a BAL was performed 6, 24 or 72h thereafter. Eosinophil numbers were determined on cytospin preparations
stained with Diff-Quik
® stain and MBP was measured in the cell-free supernatant of BAL fluid using a specific double sandwitch
ELISA. Results are means ± SEM of six experiments. *P < 0.05, compared with saline-challenged vehicle-treated guinea-pigs.
†P < 0.05, compared with ovalbumin-challenged vehicle-treated guinea-pigs.An augmented number of CD4+ T-lymphocytes was
also  noted in  the  bronchial  submucosa  from  sensi-
tized  vehicle-treated  guinea-pigs  after  ovalbumin,
particularly at 6 and 72h (Fig. 5). FK506 was effective
in  reducing  such  infiltration  down  to  the levels  of
saline-challenged vehicle-treated animals (Fig. 5). The
numbers  of  CD8+ T  cells  were  not  increased  in
antigen-challenged  guinea-pigs  and  they  were  not
modified  after  treatment  with  FK506  (data  not
shown).
The  presence  of  cells  expressing  a 4-integrins,
adhering  to  the  vascular  endothelium  and  infiltrat-
ing  the  perivascular  compartment  at  the  different
time-points  was  then  examined  (Fig.  6). The  num-
ber  of  a 4-integrin  positive  cells  was  significantly
increased 6h, but not 24 and 72h after ovalbumin
administration.  At  this  time-point,  FK506  reduced
considerably  the  number  of  cells  adhered  to  the
endothelium  or  transmigrating  into  the  tissues
(Fig.  6).
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FIG. 3. Effect of FK506 on antigen-induced eosinophil infiltration in the bronchial mucosa from sensitized guinea-pigs. EPO
+
cells in the bronchial submucosa (panel A) and in the adventitia (panel B) of sensitized guinea-pigs challenged with intranasal
saline  or  ovalbumin and  treateds.c.  with  0.5mg/kg  of  FK506, 1h  before  and  5h  after  antigen challenge. Animals  were
challenged and lungs removed 6, 24 or 72h thereafter. Results are means ± SEM of six experiments. *P < 0.05, compared with
saline-challenged vehicle-treated guinea-pigs. †P < 0.05, compared with ovalbumin-challenged challenged vehicle-treated
guinea-pigs.
FIG. 4. Time-course of the effect of FK506 on antigen-induced T-lymphocyte accumulation in the bronchial submucosa (panel
A) and in the adventitia (panel B) from sensitized guinea-pigs (CT5 staining and APAAP). Sensitized vehicle-or FK506 (0.5mg/
kg)-treated animals were challenged with aerosolized saline or ovalbumin and lungs collected 6, 24 or 72h thereafter. Results
are means ± SEM of six experiments. *P < 0.05, compared with saline-challenged vehicle-treated guinea-pigs. †P < 0.05,
compared with ovalbumin-challenged vehicle-treated guinea-pigs.Discussion
In the present study, we demonstrated that i.n. antigen
challenge of sensitized guinea-pigs was followed by an
early  and transient increase in  the number  of  cells
adherent  to  pulmonary  vascular  endothelium  and
expressing a 4-integrins. Although we were unable to
distinguish these cells by lack of reagents for perform-
ing double staining, the possibility that they could be
identified as T-lymphocytes and eosinophils appears
likely. Indeed, a 4-integrin expression was first accom-
panied (at 6h) and then followed (at 24 and 72h) by
the infiltration of eosinophils and CD4+T-lymphocytes
in  the  bronchial  mucosa,  two  cell  types  which
preferentially express a 4-integrins on their surface.17
While the rise in the number of a 4-integrin positive
cells occurred as early as 6h after the challenge and
decreased thereafter, the invasion of the bronchial wall
by eosinophils and T-cells remained at a plateau for at
least 72h. Furthermore, no staining for a 4-integrins
was observed in the bronchial submucosa of antigen-
challenged guinea-pigs at any time-point. Treatment of
the sensitized guinea-pigs with FK506 prevented the
adherence of a 4-integrin positive cells to the vascular
endothelium  at  6h  and  abrogated  the  subsequent
infiltration of eosinophils and T-cells in the bronchial
mucosa  and  BAL  fluid.  Whether  the  inhibition  of
leukocyte  recruitment  into  the  bronchial  wall  by
FK506 is directly or indirectly related to a blockade of
adhesion molecules expression is an attractive hypoth-
esis which deserves further investigations.
The ability of FK506 to down-regulate T-cell activa-
tion has been demonstrated.19This is translated into a
decreased production of cytokines, including IL-4 and
TNF-a ,  which  directly  facilitate  the  induction  of
adhesion  molecules  on  endothelial  cells.30,31
T-lymphocytes are also a source of other cytokines,
such as IL-3, IL-5 and GM-CSF, which influence directly
many aspects of eosinophil biology, including mobili-
zation  and  activation,  as  well  as  the  growth  and
differentiation from eosinophil precursors.32 Indeed,
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FIG. 5. Kinetics of the effect of FK506 on antigen-induced CD4
+ T-lymphocyte infiltration into the bronchial mucosa of sensitized
guinea-pigs (H155 staining and immunoperoxidase). Sensitized vehicle- or FK506 (0.1mg/kg)-treated animals were challenged
with intra-nasal saline or ovalbumin and lungs collected 6, 24 or 72h thereafter. Results are means ± SEM of six experiments.
*P < 0.05, compared with saline-challenged vehicle-treated guinea-pigs. †P < 0.05, compared with ovalbumin-challenged
vehicle-treated guinea-pigs.
FIG. 6. Effect of FK506 on antigen-induced accumulation of
a 4  integrin  positive  cells  in  pulmonary  endothelium  and
perivascular compartment from sensitized guinea-pigs (HP1/
2 staining and APAAP). Sensitized vehicle- or FK506 (0.5mg/
kg)-treated animals were challenged with intra-nasal saline
or ovalbumin and lungs were used at 6, 24 or 72h. Results
are means ± SEM of six experiments. *P < 0.05, compared
with saline-challenged vehicle-treated guinea-pigs. †P < 0.05,
compared  with  ovalbumin-challenged  vehicle-treated
guinea-pigs.the total number of T-cells and of CD4+T-lymphocytes
in the bronchial mucosa of antigen-challenged FK506-
treated guinea-pigs was decreased down to the values
of saline-exposed animals. One possible explanation
for  this  phenomenon  came  from  a  recent  study
showing that FK506 augmented the apoptosis of CD3-
activated CD4+ and CD8+T-lymphocytes in mice.33
In our model, ovalbumin inhalation was followed
by the accumulation of activated eosinophils in the
BAL  fluid  from  sensitized  guinea-pigs.  Eosinophil
activation was expressed by a rise in the levels of MBP
in the cell-free supernatant of BAL fluid collected 24
and 72h after antigen challenge. Both accumulation
and MBP release were abolished by the administration
of  FK506. This  probably  derives from  the effect of
FK506  on  T-lymphocytes  and  the  release  of  IL-5,
which leads to the blockage of eosinophil recruitment
and accumulation in the lungs.
The T-cell dependency of allergic airway inflamma-
tion and bronchial hyperreactivity has been already
investigated  in  different  species,  particularly  the
mouse. Thus, depletion of CD4+T-lymphocytes on one
hand,34 and treatment with some immunosuppressors,
including FK506,35 on the other hand, prevent BAL
eosinophilia and the accompanying increase in bron-
chial sensitivity to spasmogens. Recently, it has been
shown that the tacrolimus analogue cyclosporin-A can
inhibit airway eosinophilic inflammation by suppress-
ing IL-5 synthesis by T-cells.36
In conclusion, we provide evidence that, probably
by  acting  on  the  early  steps  involved  in  leukocyte
transmigration  and  infiltration  into  the  bronchial
lumen,  the immunosuppressor tacrolimus abrogates
most of the features of allergic airway inflammation in
the guinea-pig, as well as their consequences on the
alterations in lung function.
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